Iron Chelation Therapy (Advances in Experimental Medicine and Biology, 509)

個数:

Iron Chelation Therapy (Advances in Experimental Medicine and Biology, 509)

  • 提携先の海外書籍取次会社に在庫がございます。通常3週間で発送いたします。
    重要ご説明事項
    1. 納期遅延や、ご入手不能となる場合が若干ございます。
    2. 複数冊ご注文の場合、分割発送となる場合がございます。
    3. 美品のご指定は承りかねます。
  • 【入荷遅延について】
    世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
    おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。
  • ◆画像の表紙や帯等は実物とは異なる場合があります。
  • ◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
    また、洋書販売価格は、ご注文確定時点での日本円価格となります。
    ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。
  • 製本 Hardcover:ハードカバー版/ページ数 280 p.
  • 言語 ENG
  • 商品コード 9780306467851
  • DDC分類 616.396

Full Description

Within the last few years, iron research has yielded exciting new insights into the under­ standing of normal iron homeostasis. However, normal iron physiology offers little protec­ tion from the toxic effects of pathological iron accumulation, because nature did not equip us with effective mechanisms of iron excretion. Excess iron may be effectively removed by phlebotomy in hereditary hemochromatosis, but this method cannot be applied to chronic anemias associated with iron overload. In these diseases, iron chelating therapy is the only method available for preventing early death caused mainly by myocardial and hepatic iron toxicity. Iron chelating therapy has changed the quality of life and life expectancy of thalassemic patients. However, the high cost and rigorous requirements of deferoxamine therapy, and the significant toxicity of deferiprone underline the need for the continued development of new and improved orally effective iron chelators. Such development, and the evolution of improved strategies of iron chelating therapy require better understanding of the pathophysiology of iron toxicity and the mechanism of action of iron chelating drugs. The timeliness of the present volume is underlined by several significant develop­ ments in recent years. New insights have been gained into the molecular basis of aberrant iron handling in hereditary disorders and the pathophysiology of iron overload (Chapters 1-5).

Contents

Pathopysiology of Iron Overload.- 1.Animal Models of Hereditary Iron Transport Disorders.- 2.Mechanism of Iron Toxicity.- 3.Role of Non-Transferrin-Bound Iron in the Pathogenesis of Iron Overload and Toxicity.- 4.Intacellular and Extracellular Labile Iron Pools.- 5.Cardioprotective Effect of Iron Chelators.- Chelation Therapy in Transfulional Siderosis.- 6.Results of Long Term Iron Chelation Treatment with Deferoxamine.- 7.Long Term Deferiprone Chelation Therapy.- Development of New Iron Chelators.- 8.Iron Chelator Chemistry.- 9.Structure-Activity Relationships Among Desazadesferrithiocin Analogues.- 10.ICL670A: Preclinical Profile.- 11.Pyridoxal Isonicotinoyl Hydrazone and Its Analogues.- Novel Strategies in Iron Chelation Treatment.- 12.Therapeutic Potential of Iron Chelators in Cancer Therapy.- 13.Antimalarial Effect of Iron Chelators.